北京若生智能科技有限公司
Drug Database
PR

propranolol

✓ Approved

Bausch + Lomb Corporation · ADRB1 · 小分子

什么是 propranolol？

propranolol 是一种小分子，由Bausch + Lomb Corporation研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

公司Bausch + Lomb Corporation
药物类别小分子
分子靶点ADRB1, ADRB2
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Bausch + Lomb Corporation

作用机制

分子靶点

propranolol 作用于 2 个分子靶点：

ADRB1adrenoceptor beta 1 (B1AR, RHR)
ADRB2adrenoceptor beta 2 (B2AR, ADRBR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

propranolol 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedJACC. Case reports2026-10-25

Continuous Stellate Ganglion Block Bridging to Cardiac Sympathetic Denervation in a Long QT Syndrome Neonate.

Meynet Pierre P, Mossetti Valeria V, Guerrera Francesco F, Ruffini Enrico E et al.

Congenital long QT syndrome (LQTS) with neonatal onset carries a high risk of drug-refractory ventricular arrhythmias. Continuous percutaneous left stellate ganglion block (PLSGB) as a bridge to left cardiac sympathetic denervation (LCSD) is unexplored in neonates. We present a newborn female with in utero onset LQTS, complicated by functional 2:1 atrioventricular block and torsades de pointes (TdP). Despite pacemaker implantation, propranolol, and mexiletine, TdP recurred. At 25 days of life, continuous PLSGB with ropivacaine suppressed TdP. At 4 months, video-assisted thoracoscopic surgery (VATS)-LCSD was performed, with no ventricular arrhythmia recurrence in 24 months. First reported case of continuous PLSGB in a neonate with LQTS; among the few VATS-LCSD cases under 1 year. Early sympathetic neuromodulation should be considered in high-risk pediatric LQTS when medical therapy fails, as a bridge to LCSD. VATS-LCSD is feasible and safe even under 1 year.

PMID 42927478
阅读全文 →
PubMedThe journal of trauma and acute care surgery2026-10-23

β-Blockade reprograms trauma-induced changes in bone marrow exosomal microRNAs.

Yoham Athina L AL, Bible Letitia E LE, Kannan Kolenkode B KB, Peethala Agneta F AF et al.

Severe trauma produces sustained sympathetic activation that contributes to bone marrow dysfunction, impaired hematopoiesis, and persistent injury-associated anemia. Although β-adrenergic blockade improves bone marrow recovery after injury, the downstream mechanisms remain incompletely defined. We hypothesized that propranolol reprograms trauma-induced bone marrow extracellular vesicle (EV) microRNA (miRNA) expression toward restoration of hematopoietic homeostasis. Sprague-Dawley rats were randomized to naïve, polytrauma (PT), PT plus propranolol (PT+BB), PT with chronic restraint stress (PTRS), or PTRS plus propranolol (PTRS+BB) groups (n=6-8 per group). Propranolol (10 mg/kg intraperitoneally) was administered daily. On day 7, complete blood counts were obtained, and bone marrow-derived EV miRNAs were profiled using the NanoString nCounter platform. Differentially expressed miRNAs were identified using an absolute log2 fold change ≥1.5 and p<0.05. Predicted pathways were assessed using Ingenuity Pathway Analysis, and miR-125b-5p was validated by quantitative PCR. PT altered 45 EV miRNAs compared with naïve animals, including suppression of miRNAs involved in hematopoietic stem cell maintenance and erythropoiesis. Chronic restraint stress amplified this response, with 93 differentially expressed miRNAs following PTRS. Propranolol altered 12 miRNAs after PT and 43 after PTRS, increasing hematopoietic regulatory miRNAs, including miR-125b-5p, while suppressing several stress- and inflammation-associated miRNAs. Pathway analysis identified alterations in NOTCH, RUNX1, PTEN, thyroid receptor/retinoid X receptor, and histone modification signaling. Quantitative PCR confirmed a 2.4-fold increase in EV miR-125b-5p following propranolol in PTRS animals (p=0.018). Trauma and persistent adrenergic stress broadly remodel bone marrow EV miRNA signaling. β-Adrenergic blockade selectively reprograms these networks toward pathways associated with hematopoietic recovery, identifying EV miRNAs as potential mediators of posttraumatic bone marrow dysfunction. Not applicable-Animal research.

PMID 42913416
阅读全文 →
PubMedJournal of mathematical biology2026-10-22

Modeling and parameter estimation of tumor spheroids from bottom-view imaging: beyond the spherical assumption.

Delaunay Tiphaine T, Laanani Faiza F, Pechtimaldjian Léa L, Oucherif Sandra S et al.

Tumor spheroids are widely used in vitro models for studying tumor growth and treatment response, yet their analysis is often limited by incomplete geometric measurements. In practice, only a two-dimensional bottom view is available, which can lead to strong biases when spheroids deviate from an ideal spherical shape, in particular for flattened aggregates. We propose a mechanistic modeling and data assimilation framework that accounts for both poor data quality and model uncertainty. A biologically motivated partial differential equations model with axial symmetry is introduced and reduced to a low-dimensional system compatible with sparse observations and ellipsoidal shapes. Uncertainties in initial conditions and parameters are handled using a Luenberger-type observer coupled with a reduced-order unscented Kalman filter. The approach is validated on synthetic data and applied to experimental in vitro spheroid data under propranolol treatment, illustrating how model-based integration of limited measurements improves the interpretation of spheroid growth dynamics and treatment-induced morphological changes.

PMID 42907589
阅读全文 →
PubMedInternational journal of pediatric otorhinolaryngology2026-10-22

Pharmacological management of vestibular migraine of childhood in a pediatric vestibular program.

DiBlasi Marco M, Pandiscio Kyle K, Yun Alice A, Kim Hae-Young HY et al.

To compare the efficacy and tolerability of medications used to treat pediatric vestibular migraine. This retrospective analysis at a quaternary pediatric vestibular program identified patients ≤18 years old with vestibular migraine of childhood (VMC), probable VMC, or recurrent vertigo of childhood per the 2021 Bárány Society diagnostic criteria. Preventative medications included cyproheptadine, propranolol, topiramate, amitriptyline, nortriptyline, venlafaxine, and duloxetine. Rescue medications included triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and meclizine. Patient characteristics were obtained. Changes in headache and dizziness symptoms were classified as no improvement, minor improvement, major improvement, or complete resolution. Generalized estimating equations compared the proportion of patients with at least major improvement for each medication. 160 patients were included [mean (SD) age 12.8 (3.9) years; 70% female]. Among preventatives, the proportion of patients who experienced at least major improvement was greatest for topiramate, with a significant difference relative to the lowest performer, cyproheptadine, for dizziness (67.6% vs. 37.5%, p < 0.001) and headache (69.4% vs. 37.5%, p < 0.001). Among rescue medications, triptans outperformed meclizine in dizziness (40.0% vs. 12.5% p = 0.048) and headache (42.7% vs. 5.6%, p = 0.019), and outperformed NSAIDs in dizziness (40.0% vs. 11.5%, p = 0.021). Age, sex, anxiety, depression, or concussion history did not influence treatment outcomes for any medication. For pediatric vestibular migraine prevention, topiramate showed superior improvement in dizziness and headache with acceptable tolerability. Triptans performed the best among rescue medications. This highlights topiramate as a potential first line preventative and supports triptans in treating pediatric vestibular migraine attacks.

PMID 42906226
阅读全文 →
PubMedChemistryOpen2026-10-19

Efficient Propranolol Delivery Enabled by Manganese-Based Bioactive Metal-Organic Frameworks With High Loading Capacity.

Borhanipasvisheh Hanieh H, Dehghani Siyahaki Soheil S, Gholamhosseinzadeh Elham E

A green and efficient method was developed for propranolol delivery utilizing manganese-based bioactive metal-organic frameworks (MOFs) as biocompatible drug carriers. Mn-based bioactive MOFs with a high aspect ratio were synthesized and characterized for size (average, 17 µm), morphology, stability, elemental composition, crystallinity, functionality, charge character, and biocompatibility (a protein adsorption capacity of 0.03 µg µg-1 (5 h) and a hemolysis ratio of < 0.5%). Afterward, the MOFs were utilized for drug loading via an encapsulation method, and the drug release studies were also performed. The drug loading was confirmed using the zeta potential, CHN analysis, and thermogravimetric analysis (TGA) measurements. An encapsulation efficiency of 96% (0.5 W/W (drug/MOFs)) and a maximal capacity (Qmax) of 0.526 mg mg-1 were obtained. The drug release showed that 93.72% of the loaded drug was released after 10 h for a composite of 0.25 W/W (drug/MOFs), while for 0.5 W/W (drug/MOFs), the drug release reached a plateau after 3 h. The kinetic studies showed longer release times and higher release rates for higher drug loading efficiency. Overall, herein, a bioactive platform for efficient delivery of propranolol was developed to improve the therapeutic efficacy by enhancing the drug loading and achieving controlled drug release.

PMID 42894273
阅读全文 →
PubMedFrontiers in pediatrics2026-10-17

Case Report: Early-onset portal hypertension revealing pediatric ADPKD with a truncating PKD1 variant.

Minota Idarraga Ana Katerin AK, Llanos Arango Ivan Mauricio IM

Autosomal dominant polycystic kidney disease (ADPKD) is a multisystemic ciliopathy whose clinical spectrum extends into childhood. Although hepatic cysts are the most common extrarenal manifestation, early portal hypertension associated with congenital hepatic fibrosis (CHF)-like features is uncommon and likely underrecognized. We report a 10-year-old girl with no known family history of ADPKD who presented at 9 years of age with upper gastrointestinal bleeding secondary to grade III esophageal varices. The diagnostic evaluation established non-cirrhotic portal hypertension, and she underwent endoscopic variceal ligation followed by secondary prophylaxis with propranolol. Imaging demonstrated hepatosplenomegaly, patent portal and splenic veins, and no hepatic cysts. Liver biopsy showed mild portal fibrosis (METAVIR F1), while liver stiffness measured 6.4 kPa, consistent with mild fibrosis. Renal imaging revealed multiple bilateral cortical cysts, and whole-exome sequencing identified a heterozygous truncating PKD1 variant (p.Glu1633Ter), classified as pathogenic according to ACMG criteria. The patient remains clinically stable without recurrent bleeding during multidisciplinary follow-up. This case expands the phenotypic spectrum of pediatric ADPKD by illustrating clinically significant portal hypertension despite only mild hepatic fibrosis. It also highlights the importance of integrating histopathology, non-invasive liver assessment, imaging, and molecular testing when evaluating children with unexplained non-cirrhotic portal hypertension. ADPKD should be considered in the differential diagnosis of pediatric non-cirrhotic portal hypertension, even in the absence of hepatic cysts. Early genetic testing may facilitate accurate diagnosis and appropriate multidisciplinary management.

PMID 42889748
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多propranolol